A Cambridge, Mass., biotech startup is using a new method to gauge the health of synapses in people’s brains as it prepares to test an experimental medicine to treat Alzheimer’s disease, the great white whale for drug makers.

Rodin Therapeutics said Thursday it has begun testing a recently developed radioactive chemical that binds with a protein present in synapses, structures that allow nerve cells to pass electrical or chemical signals to each other.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

  • I had an MRI done approx 2 weeks ago due to continued memory issues, also have seizures after contracting whooping cough 11 years ago from someone not vaccinated. The scan showed scattered white matter, I am 59 years old, can this be from the activity, severe lack of sleep or is this a sign of the beginning of EOD or Alzheimers?

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy